Clinical trial

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785

Study summary

ClinicalTrials.gov

Natural Killer Cells and Bortezomib to Treat Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Bortezomib Normalized identity: bortezomib View linked drug · Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention NK cells Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-08-01

PhasePHASE1

Conditions

Chronic Myeloid Leukemia (CML)unresolved

Pancreatic Caunresolved

Colon/Rectal Caunresolved

Multiple Myelomaunresolved

Carcinoma, Non-Small -Cell Lungunresolved

Interventions

BortezomibDRUG · verified · RxNorm: bortezomib

NK cellsBIOLOGICAL

Sponsors & collaborators

National Heart, Lung, and Blood Institute (NHLBI)lead sponsor

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00720785 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.